Congratulations to our client, MYCAPSSA! On June 26, 2020 the FDA approved Chiasma Inc.’s MYCAPSSA®(octreotide) capsules for oral treatment of acromegaly, utilizing Chiasma’s Transient Permeability Enhancer (TPE®) technology. Michal Rom of Pearl Cohen’s Corporate and Licensing Group advised Chiasma on the set-up and management of its phase III, worldwide and multi-centre clinical trials performed with MYCAPSSA.
Congratulations to our client MYCAPSSA
Client Updates / June 30, 2020
